Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors

Iacopo Sardi, Valentina Cetica, Maura Massimino, Anna Maria Buccoliero, Laura Giunti, Lorenzo Genitori, Maurizio Aricò

Research output: Contribution to journalArticle

Abstract

Insufficient response to oral temozolomide (TMZ) in children with brain tumor may depend on the repair-action of inducible O6-methylguanine-DNA methyltransferase (MGMT). To investigate the clinical relevance of MGMT expression, we analyzed MGMT levels by qRT-PCR and immunohistochemistry, and the methylation of gene promoter in patients with relapsed or refractory brain tumor, enrolled in an off-label trial with oral temozolomide. The drug was administered at the dose of 200 mg/m2/day in patients with no prior cranio-spinal irradiation, and 180 mg/m2/day in those with previous radiotherapy and/or high-dose chemotherapy followed by autologous hematopoietic stem cell rescue. Nine patients with recurrent ependymoma (n=3), low grade glioma (n=3), glioblastoma (n=1), relapsed medulloblastoma (n=2) were enrolled in the study. Median absolute MGMT mRNA expression level standardized for GAPDH was 1.06 (range -0.453 to 3.932). The median relative expression level (RQ=2-ddC) was 4.29 (range 1.585 to 12.228). By immunohistochemistry, the score was 2+ in 6 of the 9 tumor samples, and 1+ in 3, while none was MGMT negative. Methylation of MGMT promoter was detected in only one ependymoma sample. The heterogeneous PFS in our patients treated with second line TMZ, indicates that MGMT expression alone is insufficient to predict the response to TMZ, presumably because of the DNA repair mechanisms involved.

Original languageEnglish
Pages (from-to)773-779
Number of pages7
JournalOncology Reports
Volume22
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

temozolomide
Methyltransferases
Brain Neoplasms
Methylation
Pediatrics
DNA
Ependymoma
Immunohistochemistry
Medulloblastoma
DNA Methylation
Glioblastoma
Hematopoietic Stem Cells
Glioma
DNA Repair
Radiotherapy
Drug Therapy
Polymerase Chain Reaction
Messenger RNA
Pharmaceutical Preparations
Genes

Keywords

  • Alkylanting agents
  • Expression analysis
  • O-methylguanine-DNA methyltransferase
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sardi, I., Cetica, V., Massimino, M., Buccoliero, A. M., Giunti, L., Genitori, L., & Aricò, M. (2009). Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. Oncology Reports, 22(4), 773-779. https://doi.org/10.3892/or_00000499

Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. / Sardi, Iacopo; Cetica, Valentina; Massimino, Maura; Buccoliero, Anna Maria; Giunti, Laura; Genitori, Lorenzo; Aricò, Maurizio.

In: Oncology Reports, Vol. 22, No. 4, 2009, p. 773-779.

Research output: Contribution to journalArticle

Sardi, I, Cetica, V, Massimino, M, Buccoliero, AM, Giunti, L, Genitori, L & Aricò, M 2009, 'Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors', Oncology Reports, vol. 22, no. 4, pp. 773-779. https://doi.org/10.3892/or_00000499
Sardi, Iacopo ; Cetica, Valentina ; Massimino, Maura ; Buccoliero, Anna Maria ; Giunti, Laura ; Genitori, Lorenzo ; Aricò, Maurizio. / Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. In: Oncology Reports. 2009 ; Vol. 22, No. 4. pp. 773-779.
@article{24d6a329617e47e9b92056b03a912bf2,
title = "Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors",
abstract = "Insufficient response to oral temozolomide (TMZ) in children with brain tumor may depend on the repair-action of inducible O6-methylguanine-DNA methyltransferase (MGMT). To investigate the clinical relevance of MGMT expression, we analyzed MGMT levels by qRT-PCR and immunohistochemistry, and the methylation of gene promoter in patients with relapsed or refractory brain tumor, enrolled in an off-label trial with oral temozolomide. The drug was administered at the dose of 200 mg/m2/day in patients with no prior cranio-spinal irradiation, and 180 mg/m2/day in those with previous radiotherapy and/or high-dose chemotherapy followed by autologous hematopoietic stem cell rescue. Nine patients with recurrent ependymoma (n=3), low grade glioma (n=3), glioblastoma (n=1), relapsed medulloblastoma (n=2) were enrolled in the study. Median absolute MGMT mRNA expression level standardized for GAPDH was 1.06 (range -0.453 to 3.932). The median relative expression level (RQ=2-ddC) was 4.29 (range 1.585 to 12.228). By immunohistochemistry, the score was 2+ in 6 of the 9 tumor samples, and 1+ in 3, while none was MGMT negative. Methylation of MGMT promoter was detected in only one ependymoma sample. The heterogeneous PFS in our patients treated with second line TMZ, indicates that MGMT expression alone is insufficient to predict the response to TMZ, presumably because of the DNA repair mechanisms involved.",
keywords = "Alkylanting agents, Expression analysis, O-methylguanine-DNA methyltransferase, Temozolomide",
author = "Iacopo Sardi and Valentina Cetica and Maura Massimino and Buccoliero, {Anna Maria} and Laura Giunti and Lorenzo Genitori and Maurizio Aric{\`o}",
year = "2009",
doi = "10.3892/or_00000499",
language = "English",
volume = "22",
pages = "773--779",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors

AU - Sardi, Iacopo

AU - Cetica, Valentina

AU - Massimino, Maura

AU - Buccoliero, Anna Maria

AU - Giunti, Laura

AU - Genitori, Lorenzo

AU - Aricò, Maurizio

PY - 2009

Y1 - 2009

N2 - Insufficient response to oral temozolomide (TMZ) in children with brain tumor may depend on the repair-action of inducible O6-methylguanine-DNA methyltransferase (MGMT). To investigate the clinical relevance of MGMT expression, we analyzed MGMT levels by qRT-PCR and immunohistochemistry, and the methylation of gene promoter in patients with relapsed or refractory brain tumor, enrolled in an off-label trial with oral temozolomide. The drug was administered at the dose of 200 mg/m2/day in patients with no prior cranio-spinal irradiation, and 180 mg/m2/day in those with previous radiotherapy and/or high-dose chemotherapy followed by autologous hematopoietic stem cell rescue. Nine patients with recurrent ependymoma (n=3), low grade glioma (n=3), glioblastoma (n=1), relapsed medulloblastoma (n=2) were enrolled in the study. Median absolute MGMT mRNA expression level standardized for GAPDH was 1.06 (range -0.453 to 3.932). The median relative expression level (RQ=2-ddC) was 4.29 (range 1.585 to 12.228). By immunohistochemistry, the score was 2+ in 6 of the 9 tumor samples, and 1+ in 3, while none was MGMT negative. Methylation of MGMT promoter was detected in only one ependymoma sample. The heterogeneous PFS in our patients treated with second line TMZ, indicates that MGMT expression alone is insufficient to predict the response to TMZ, presumably because of the DNA repair mechanisms involved.

AB - Insufficient response to oral temozolomide (TMZ) in children with brain tumor may depend on the repair-action of inducible O6-methylguanine-DNA methyltransferase (MGMT). To investigate the clinical relevance of MGMT expression, we analyzed MGMT levels by qRT-PCR and immunohistochemistry, and the methylation of gene promoter in patients with relapsed or refractory brain tumor, enrolled in an off-label trial with oral temozolomide. The drug was administered at the dose of 200 mg/m2/day in patients with no prior cranio-spinal irradiation, and 180 mg/m2/day in those with previous radiotherapy and/or high-dose chemotherapy followed by autologous hematopoietic stem cell rescue. Nine patients with recurrent ependymoma (n=3), low grade glioma (n=3), glioblastoma (n=1), relapsed medulloblastoma (n=2) were enrolled in the study. Median absolute MGMT mRNA expression level standardized for GAPDH was 1.06 (range -0.453 to 3.932). The median relative expression level (RQ=2-ddC) was 4.29 (range 1.585 to 12.228). By immunohistochemistry, the score was 2+ in 6 of the 9 tumor samples, and 1+ in 3, while none was MGMT negative. Methylation of MGMT promoter was detected in only one ependymoma sample. The heterogeneous PFS in our patients treated with second line TMZ, indicates that MGMT expression alone is insufficient to predict the response to TMZ, presumably because of the DNA repair mechanisms involved.

KW - Alkylanting agents

KW - Expression analysis

KW - O-methylguanine-DNA methyltransferase

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=70350371090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350371090&partnerID=8YFLogxK

U2 - 10.3892/or_00000499

DO - 10.3892/or_00000499

M3 - Article

C2 - 19724855

AN - SCOPUS:70350371090

VL - 22

SP - 773

EP - 779

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -